The crude polysaccharide extracted from was chemically modified to obtain carboxymethylated derivatives (CM-CPS) and acetylated derivatives (AC-CPS). The physicochemical characterizations were comparatively investigated by chemical methods, high-performance gel permeation chromatography, FT-IR spectra, NMR analysis, Congo red test, scanning electron microscopy, atomic force microscopy and differential scanning calorimetry. Then α-glucosidase inhibitory activities were conducted to determine the structure-bioactivity relationship. Results indicated that carboxymethylation and acetylation modification of polysaccharide were successful with the carboxymethyl substitutions might being C-6, C-2 and acetyl substitutions at C-3, C-6 inferred from NMR analysis. In addition, the tertiary structure, ultrastructure, melting properties were also different from native polysaccharide. Besides, α-glucosidase inhibitory activities of derivatives exhibited differently with CM-CPS to be the lowest. Therefore, it was concluded that change of structure in polysaccharide had certain effect on bioactivity with degree of substitution and substituents position being the influence factors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/14786419.2018.1533830 | DOI Listing |
Eur J Clin Microbiol Infect Dis
January 2025
Department of Medical Microbiology, PGIMER, Chandigarh, Chandigarh, 160012, India.
Cefepime-tazobactam (FEP-TAZ) consists of cefepime combined with tazobactam, a penicillanic acid-sulfone recognized as an established beta-lactamase inhibitor. This study aims to investigate the in-vitro effectiveness of FEP-TAZ against cefepime-resistant clinical isolates of Escherichia coli (E. coli).
View Article and Find Full Text PDFCurr Atheroscler Rep
January 2025
Carbohydrate and Lipid Metabolism Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Purpose Of Review: Homozygous familial hypercholesterolaemia (HoFH) is characterized by marked elevation of low-density lipoprotein cholesterol (LDLC) and premature atherosclerotic cardiovascular disease. This is a review of novel pharmacological therapies to lower LDLC in patients with HoFH.
Recent Findings: Novel therapies can be broadly divided by whether their efficacy is dependent or independent of residual low-density lipoprotein receptor (LDLR) function.
Alzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Inhibitory interneurons normally regulate neural networks underlying memory and cognition, but are disrupted in Alzheimer's disease. Proper interneuron activity reduces amyloid-beta, whereas hyperexcitability elevates amyloid levels. Still, the underlying pathologic processes mediating interneuron dysfunction remain unknown.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Duke University School of Medicine, Durham, NC, USA.
Background: Patients with Alzheimer's Disease (AD) frequently manifest comorbid neuropsychiatric symptoms (NPS) with depression and anxiety being most prevalent. Previously we identified shared genetic risk loci between AD and major depressive disorder (MDD). In another study, we constructed a polygenic risk score (PRS) based on MDD-GWAS data and demonstrated its performance in predicting depression onset in LOAD patients.
View Article and Find Full Text PDFBiochem Genet
January 2025
Department of Cardiac Function, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, Hubei, China.
Lung adenocarcinoma (LUAD) is characterized by its aggressive nature and resistance to treatment. FAM107A is a tumor suppressor gene that has been found to possess inhibitory effects in several cancers, but its role in LUAD remains unclear. This study investigated the role of FAM107A in regulating LUAD cell growth, invasion and aerobic glycolysis and also investigated the potential underlying mechanisms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!